Novo Nordisk CEO Defends Turnaround as Investors Eye Pipeline Risks

Novo Nordisk's CEO Mike Doustdar, one year into a corporate turnaround, asserts that investors underestimate the company's drug pipeline potential. The statement comes amid investor nervousness about future growth, likely due to competitive pressures and patent cliffs. The market's reaction hinges on pipeline execution and upcoming data readouts.